Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$87.07 USD

87.07
1,712,914

-0.34 (-0.39%)

Updated Jun 5, 2024 04:00 PM ET

After-Market: $87.04 -0.03 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (141 out of 248)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

AVNS vs. EW: Which Stock Is the Better Value Option?

AVNS vs. EW: Which Stock Is the Better Value Option?

Analysts Estimate Integer (ITGR) to Report a Decline in Earnings: What to Look Out for

Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Invest in Edward Lifesciences (EW) Now

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business.

What's in Store for Edwards Lifesciences (EW) in Q2 Earnings?

Within the Transcatheter Aortic Valve Replacement (TAVR) arm, Edwards Lifesciences (EW) is likely to have witnessed continued growth in TAVR procedures globally.

908 Devices Inc. (MASS) Soars 8.5%: Is Further Upside Left in the Stock?

908 Devices Inc. (MASS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Is Caribou Biosciences (CRBU) Outperforming Other Medical Stocks This Year?

Here is how Caribou Biosciences, Inc. (CRBU) and Edwards Lifesciences (EW) have performed compared to their sector so far this year.

Edwards Lifesciences (EW) Recently Broke Out Above the 20-Day Moving Average

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Edwards' (EW) Innovation Aids Growth, Critical Care Flourishes

Edwards' (EW) Surgical Structural Heart sales growth is lifted by the increased adoption of its premium products across all regions.

Here's How Much a $1000 Investment in Edwards Lifesciences Made 10 Years Ago Would Be Worth Today

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Shilpa Mete headshot

4 GARP Stocks to Scoop Up for Maximum Returns

Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RACE, GWW, ALLE and EW are some stocks that hold promise.

Implied Volatility Surging for Edwards Lifesciences (EW) Stock Options

Investors need to pay close attention to Edwards Lifesciences (EW) stock based on the movements in the options market lately.

Edwards Lifesciences' (EW) TMTT Sales Aid Amid Margin Woes

Edwards Lifesciences (EW) continues to expect the global TAVR opportunity to increase to $10 billion by 2028.

Here's Why You Should Invest in Edward Lifesciences (EW) Now

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business and the Critical Care segment.

Edwards Lifesciences (EW) Down 5.9% Since Last Earnings Report: Can It Rebound?

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mark Vickery headshot

Top Stock Reports for Home Depot, Linde & Walt Disney

Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Linde plc (LIN) and The Walt Disney Company (DIS).

Edwards Lifesciences' (EW) TAVR Study Outcome Favorable

Edwards Lifesciences' (EW) latest findings of the study confirm the value of the Edwards Benchmark programme for standardizing clinical pathways for patients undergoing TAVR in Europe.

ITGR vs. EW: Which Stock Is the Better Value Option?

ITGR vs. EW: Which Stock Is the Better Value Option?

STERIS (STE) Q4 Earnings Beat Estimates, Gross Margin Falls

Heading into fiscal 2024, STERIS (STE) expects many of its fiscal 2023 challenges to abate, including procedure volumes and supply chain constraints.

Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates

Amid a challenging economic environment, Haemonetics (HAE) delivers impressive fiscal fourth-quarter organic revenues, led by the stellar performance across the Plasma and Hospital business.

Alcon (ALC) Q1 Earnings Surpass Estimates, 23' EPS View Up

Alcon (ALC) Q1 revenues were driven by strong consumables and equipment sales.

Here's Why You Should Retain Walgreens Boots (WBA) For Now

Investors are optimistic about Walgreens Boots (WBA) on consistent partnership growth and a strong focus on strategic execution.

Charles River (CRL) Q1 Earnings Top Estimates, View Narrowed

Charles River (CRL) registers robust growth in small research models, research model services and the Cell Solutions business.

NuVasive (NUVA) Q1 Earnings Beat Estimates, Margins Fall

NuVasive's (NUVA) strong sales across the U.S. Spinal Hardware and U.S. Surgical Support businesses instill optimism.

Syneos Health (SYNH) Tops Q1 Earnings, Announces Merger Plan

Syneos Health's (SYNH) first-quarter 2023 earnings and revenues beat estimates. The company enters into a definitive merger agreement to be acquired by a private investment consortium.